Loading...

FSD Pharma Inc.

HUGE•NASDAQ
Healthcare
Drug Manufacturers - Specialty & Generic
$0.09
$-0.01(-10.10%)

FSD Pharma Inc. (HUGE) Stock Overview

Explore FSD Pharma Inc.’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.9/100

Key Financials

Market Cap66.7K
P/E Ratio-0.86
EPS (TTM)$-16.25
ROE-0.56%

AI Price Forecasts

1 WeekN/A
1 MonthN/A
3 MonthsN/A
1 Year Target$22.37

HUGE Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of FSD Pharma Inc. (HUGE) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $22.37.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -0.86 and a market capitalization of 66.7K. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Stats data is not available for HUGEStats details for HUGE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for HUGEAnalyst Recommendations details for HUGE are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

FSD Pharma Inc., through its subsidiaries, operates as a pharmaceutical research and development company. Its lead candidate includes FSD-201 that is in the Phase II clinical trial to treat COVID-19 disease. The company also focuses on Lucid-PSYCH, a psychoactive molecule identified for the potential treatment of neuropsychiatric disorders, such as depressive disorder; and Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. FSD Pharma Inc. was founded in 1998 and is headquartered in Toronto, Canada.

CEO

Mr. Zeeshan Saeed

Employees

17

Headquarters

199 Bay Street, Toronto, ON

Founded

2018

Frequently Asked Questions

;